Zeta CD57 Antibody. Zeta’s recombinant mouse antibody recognizes CD57, which is expressed on a subpopulation of 15-20% of peripheral blood mononuclear cells, about 60% of NK active cells and on a subset of T cells. Clone NK1 marks a subset of lymphocytes known as natural killer (NK) cells. Clone NK1 also reacts with a variety of cell types in non-lymphoid tissues. It stains neuroendocrine cells and their tumors.
CD57 (also called Leu7, beta-1,3-glucuronyltransferase 1 and glucuronosyltransferase P) is a glycoprotein with cell adhesion functions that may define a phenotype associated with replicative senescence in HIV specific CD8+ T cells. CD57 is a marker of NK cells and neuroendocrine tumors, helps distinguish high grade prostatic adenocarcinoma (CD57+) from high grade urothelial carcinoma (CD57-).
In normal cells, the CD57 antibody stains NK subset, T cell subset, neuroectodermal tissue, retina, brain, prostate and renal proximal tubules. In disease, CD57 is express in leukemias and lymphomas for autoimmune lymphoproliferative syndrome, hepatosplenic T cell lymphoma (some), nodular lymphocyte predominant Hodgkin lymphoma, pre T-ALL (occasional) and T-cell large granular lymphocytic leukemia. It is also helpful for nerve sheath origin lesions including benign epithelioid nerve sheath tumor, chordoma, dendritic cell neurofibroma with pseudorosettes, melanotic neuroectodermal tumor of infancy, MPNST (expression decreases with tumor grade, and nerve sheath myxoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.